The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 05, 2023
Filed:
Mar. 18, 2020
Applicant:
Epizyme, Inc., Cambridge, MA (US);
Inventors:
Richard Chesworth, Concord, MA (US);
Oscar Miguel Moradei, Burlington, MA (US);
Gideon Shapiro, Gainesville, FL (US);
Lei Jin, Wellesley, MA (US);
Robert E. Babine, Carlsbad, CA (US);
Assignee:
Epizyme, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/10 (2006.01); C07D 403/12 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 239/42 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 487/08 (2006.01); C07D 493/04 (2006.01); C07D 493/10 (2006.01); C07D 495/04 (2006.01); C07D 498/04 (2006.01); C07D 498/10 (2006.01); C07D 413/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 487/10 (2013.01); C07D 239/42 (2013.01); C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 493/04 (2013.01); C07D 493/10 (2013.01); C07D 495/04 (2013.01); C07D 498/04 (2013.01); C07D 498/10 (2013.01);
Abstract
Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R, R, R, R, R, R, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L, R, G, G, G, and Gare as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.